ClinicalTrials.gg
CompletedNCT02003391Updated Aug 8, 2016Results posted

Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure

A Phase 4 interventional study of Beta-blocker monotherapy and Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution in Open Angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-08.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
20th of 45
157 · median 135
Started
2013
with 1 other
Phase 4
22 of 46
2 open now
Registered
37th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2013, is one of 22 in phase 4, and was the 37th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open Angle Glaucoma
  • Ocular Hypertension
  • Intraocular Pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of either open angle glaucoma or ocular hypertension.
  • Currently on beta-blocker monotherapy (for >30 days) and would benefit, in the opinion of the investigator, from further intraocular pressure (lOP) reduction.
  • Have a mean baseline lOP of >18 mmHg and \<32 mmHg in at least one eye.
  • Must be able to understand and sign an form.
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Use of medication excluded by the protocol.
  • Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol.
  • Ocular surgeries or procedures excluded by the protocol.
  • Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to 20/80 Snellen, 0.60 logMAR or 0.25 decimal).
  • to prostaglandin analogues or any component of the study medications in the opinion of the investigator.
  • Women of if pregnant, test positive for pregnancy at Screening visit, breastfeeding, or not in agreement to use adequate methods to prevent pregnancy throughout the study.
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    DuoTrav

    Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.

    Drug: Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution

  • Active comparator
    Beta-blocker

    Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.

    Drug: Beta-blocker monotherapy · Drug: Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution

Interventions

  • Per participant's current prescribed therapy

  • DrugTravoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution

    Drug page: Travoprost

    Also known as: DUOTRAV®

06

What researchers measure

Primary outcomes

  1. Least Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and is measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.

    Time frame: Week 4

Secondary outcomes

  1. Mean Change From Baseline in IOP (8AM) at Week 4 in the Study Eye

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and is measured in mmHg. A negative change indicates an improvement. One eye (study eye) contributed to the analysis.

    Time frame: Baseline (Day 0), Week 4

  2. Percentage Change From Baseline in IOP (8AM) at Week 4 in the Study Eye

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and is measured in mmHg. A more negative percent change from baseline indicates a greater amount of improvement, i.e., a reduction of IOP. One eye (study eye) contributed to the analysis.

    Time frame: Baseline (Day 0), Week 4

07

Results

Posted Aug 8, 2016

Participant flow

Participants were recruited from 14 investigational centers located in Latin America, Australia, Russia, and Korea.

Participant flow — Overall Study
MilestoneDuoTravBeta-blocker
Started8175
Safety population8175
Intent to treat population7873
Completed7873
Not completed32
Withdrew: Withdrawal by subject21
Withdrew: Protocol violation01
Withdrew: Adverse event10

Outcome measures

PrimaryLeast Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and is measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.

Time frame:
Week 4
Reported as:
Least squares mean · mmHg
Least Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye
mmHgDuoTravBeta-blocker
Least Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye16.6129 (NA to 17.1451)21.2320 (NA to 21.7858)
Statistical analysis
  • DuoTrav vs Beta-blocker · ANCOVA · p = <0.0001 · Mean difference (final values): -4.6191
SecondaryMean Change From Baseline in IOP (8AM) at Week 4 in the Study Eye

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and is measured in mmHg. A negative change indicates an improvement. One eye (study eye) contributed to the analysis.

Time frame:
Baseline (Day 0), Week 4
Reported as:
Mean · mmHg
Mean Change From Baseline in IOP (8AM) at Week 4 in the Study Eye
mmHgDuoTravBeta-blocker
Mean Change From Baseline in IOP (8AM) at Week 4 in the Study Eye-5.840 ± 3.4870-1.069 ± 2.4969
SecondaryPercentage Change From Baseline in IOP (8AM) at Week 4 in the Study Eye

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and is measured in mmHg. A more negative percent change from baseline indicates a greater amount of improvement, i.e., a reduction of IOP. One eye (study eye) contributed to the analysis.

Time frame:
Baseline (Day 0), Week 4
Reported as:
Mean · Percent Change
Percentage Change From Baseline in IOP (8AM) at Week 4 in the Study Eye
Percent ChangeDuoTravBeta-blocker
Percentage Change From Baseline in IOP (8AM) at Week 4 in the Study Eye-25.365 ± 14.2093-4.716 ± 11.4005

Adverse events

Collected over Reporting of adverse events (AEs) began once informed consent was obtained from the participant and continued through study exit at week 8. Ocular AEs are presented for both study eye and non-study eye combined.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DuoTrav—0/81 (0%)18/81 (22.2%)
Beta-blocker—0/75 (0%)9/75 (12%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventDuoTravBeta-blocker
Ocular hyperaemiaEye disorders5/810/75
Eye pruritusEye disorders4/810/75
Dry eyeEye disorders2/812/75
InfluenzaInfections and infestations0/812/75
NasopharyngitisInfections and infestations2/812/75
Conjunctivitis allergicEye disorders1/811/75
Eye irritationEye disorders1/811/75
Ocular surface diseaseEye disorders1/811/75
BronchitisInfections and infestations0/811/75
PharyngitisInfections and infestations1/811/75

Baseline characteristics

Intent to treat population included participants who received study medication and had at least one on-therapy study visit.

Age, Continuous
Age, Continuous(years)DuoTravBeta-blockerTotal
Mean62.8 ± 12.7663.8 ± 13.2963.3 ± 12.98
Sex: Female, Male
Sex: Female, Male(Participants)DuoTravBeta-blockerTotal
Female5452106
Male242145
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lerner SF, Park KH, Hubatsch DA, Erichev V, Paczka JA, Roberts TV. Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy. J Ophthalmol. 2017;2017:1917570. doi: 10.1155/2017/1917570. Epub 2017 Jan 23. PubMed 28239491 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2013
First posted
Dec 6, 2013
Start
Dec 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Aug 8, 2016
Last update
Aug 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02003391
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Dec 6, 2013
Start date
Dec 2013
Primary completion
May 2015
Completion
May 2015
Results posted
Aug 8, 2016
Last update
Aug 8, 2016

Study contacts

Clinical Project Lead GCRA, Pharma
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion